BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's ...
Add Yahoo as a preferred source to see more of our stories on Google. The trial aims to assess biological and clinical activity of TTX-MC138 in patients with MRD. Credit: Pickadook / Shutterstock.com.
(RTTNews) - TransCode Therapeutics, Inc. (RNAZ) and Quantum Leap Healthcare Collaborative, on Friday, announced a collaboration to evaluate TTX-MC138 in a Phase 2a dose-expansion trial. TTX-MC138, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results